Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US House Panel Passes Telehealth, Counterfeit Device, National Stockpile Bills In Marathon Mark-Up

Executive Summary

The House Energy and Commerce Committee swiftly passed three measures impacting medtech companies during a 15 July mark-up session.

You may also be interested in...

Much Of Telemed Legislation Emerging From New Congress Would Only Partially Solve Payment Woes

A telemedicine legislative expert explains provisions of bills that would expand reimbursement provisions in Congress.

COVID-19 Telehealth-Use Explosion Gets US Senators Crossing Party Lines To Expand Its Practice

Many US senators became telemedicine converts during this spring’s COVID-19 trial-by-fire use of the health care delivery option, and avidly pushed bills to back it at a mid-June hearing.

Bill To Allow FDA To Destroy Counterfeit Devices Wins Praise On Hill; J&J Exec Testifies In Support

Several US House members are backing a new piece of legislation that would give the US Food and Drug Administration the authority to destroy counterfeit devices when they arrive at points of entry into the country. A Johnson & Johnson executive who specializes in global brand protection provided dramatic testimony before a House health panel on 29 January on the need for the anti-counterfeiting bill.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts